IMMH001 is a selective and orally active S1P1 (sphingosine-1-phosphate receptor 1) agonist that reduces the levels of chemokines and pro-inflammatory cytokines, including IL-1β, IL-5, IL-18, IP10, CCL3, and CCL5; it is used in the research of rheumatoid arthritis (RA).